VERTEX PHARMACEUTICALS INC / MA Undistributed Earnings, Diluted
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Undistributed Earnings, Diluted of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Notes › Earnings Per Share
us-gaap:UndistributedEarningsDiluted · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA undistributed earnings, diluted for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA undistributed earnings, diluted for the quarter ending 2019-09-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA undistributed earnings, diluted for the quarter ending 2019-06-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA undistributed earnings, diluted for the quarter ending 2019-03-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA undistributed earnings, diluted for fiscal 2020 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA undistributed earnings, diluted for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA undistributed earnings, diluted for fiscal 2018 was $492.00K, a 70.83% increase from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA undistributed earnings, diluted for fiscal 2017 was $288.00K.
| Period end | Undistributed Earnings, Diluted 3 month | Undistributed Earnings, Diluted 3 month as first filed | Undistributed Earnings, Diluted 6 month | Undistributed Earnings, Diluted 9 month | Undistributed Earnings, Diluted 12 month | Undistributed Earnings, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-11 | |||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $0.00 derived: sum of 2 quarters · filed 2021-02-11 | $0.00 derived: sum of 3 quarters · filed 2021-02-11 | $0.00 10-K · filed 2021-02-11 | ||
| 2019-09-30 | $0.00 10-Q · filed 2019-10-31 | $0.00 derived: sum of 2 quarters · filed 2019-10-31 | $0.00 10-Q · filed 2019-10-31 | $650.00K derived: sum of 4 quarters · filed 2021-02-11 | ||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-01 | $0.00 10-Q · filed 2019-08-01 | $650.00K derived: sum of 3 quarters · filed 2021-02-11 | $637.00K derived: sum of 4 quarters · filed 2021-02-11 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-01 | $650.00K derived: sum of 2 quarters · filed 2021-02-11 | $637.00K derived: sum of 3 quarters · filed 2021-02-11 | $573.00K derived: sum of 4 quarters · filed 2021-02-11 | ||
| 2018-12-31 | $650.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $637.00K derived: sum of 2 quarters · filed 2021-02-11 | $573.00K derived: sum of 3 quarters · filed 2021-02-11 | $492.00K 10-K · filed 2021-02-11 | ||
| 2018-09-30 | -$13.00K 10-Q · filed 2019-10-31 | -$77.00K derived: sum of 2 quarters · filed 2019-10-31 | -$158.00K 10-Q · filed 2019-10-31 | $314.00K derived: sum of 4 quarters · filed 2020-02-13 | ||
| 2018-06-30 | -$64.00K 10-Q · filed 2019-08-01 | -$160.00K 10-Q · filed 2019-08-01 | $327.00K derived: sum of 3 quarters · filed 2020-02-13 | $327.00K derived: sum of 4 quarters · filed 2020-02-13 | ||
| 2018-03-31 | -$97.00K 10-Q · filed 2019-05-01 | $391.00K derived: sum of 2 quarters · filed 2020-02-13 | $391.00K derived: sum of 3 quarters · filed 2020-02-13 | $368.00K derived: sum of 4 quarters · filed 2020-02-13 | ||
| 2017-12-31 | $488.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $488.00K derived: sum of 2 quarters · filed 2020-02-13 | $465.00K derived: sum of 3 quarters · filed 2020-02-13 | $288.00K 10-K · filed 2020-02-13 | ||
| 2017-09-30 | $0.00 10-Q · filed 2018-10-25 | -$23.00K derived: sum of 2 quarters · filed 2018-10-25 | -$200.00K 10-Q · filed 2018-10-25 | -$424.00K derived: sum of 4 quarters · filed 2019-02-13 | ||
| 2017-06-30 | -$23.00K 10-Q · filed 2018-07-26 | -$382.00K 10-Q · filed 2018-07-26 | -$424.00K derived: sum of 3 quarters · filed 2019-02-13 | -$424.00K derived: sum of 4 quarters · filed 2019-02-13 | ||
| 2017-03-31 | -$401.00K 10-Q · filed 2018-04-27 | -$401.00K derived: sum of 2 quarters · filed 2019-02-13 | -$401.00K derived: sum of 3 quarters · filed 2019-02-13 | -$401.00K derived: sum of 4 quarters · filed 2019-02-13 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $0.00 derived: sum of 2 quarters · filed 2019-02-13 | $0.00 derived: sum of 3 quarters · filed 2019-02-13 | $0.00 10-K · filed 2019-02-13 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-10-30 | $0.00 derived: sum of 2 quarters · filed 2017-10-30 | $0.00 10-Q · filed 2017-10-30 | |||
| 2016-06-30 | $0.00 10-Q · filed 2017-07-28 | $0.00 10-Q · filed 2017-07-28 | ||||
| 2016-03-31 | $0.00 10-Q · filed 2017-04-28 | |||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-15 | |||||
| 2014-12-31 | $0.00 10-K · filed 2015-02-13 | |||||
| 2013-12-31 | $0.00 10-K · filed 2015-02-13 | |||||
| 2013-06-30 | $0.00 10-Q · filed 2013-08-02 | $0.00 10-Q · filed 2013-08-02 | ||||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-08 | |||||
| 2012-12-31 | -$317.00K 10-K · filed 2015-02-13 | $0.00 10-K · filed 2013-03-01 | ||||
| 2012-06-30 | $0.00 10-Q · filed 2013-08-02 | -$256.00K 10-Q · filed 2013-08-02 | ||||
| 2012-03-31 | -$860.00K 10-Q · filed 2013-05-08 | |||||
| 2011-12-31 | $285.00K 10-K · filed 2014-02-11 | |||||
| 2011-09-30 | -$2.01M 10-Q · filed 2012-11-06 | $2.01M 10-Q · filed 2011-11-03 | ||||
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |